They trimmed their workforce and expenses, after the fda shot them last year, to conserve their cash. All their efforts have been directed at Nothera, or so they said at the time. Truth is, they probably haven't done much with the rest of their pipeline.
GB, all good remarks, for me it's refreshing in the Bio world, they cut unnecessary fat at this point,
instead picking pockets of investors. Northera alone should take care of their financial needs, If approved of course.